Article Text

Download PDFPDF
The natural history of treated PD in an incident, community-based cohort: does the future begin?
  1. Giovanni Defazio
  1. Correspondence to Giovanni Defazio, Department of Neurologic and Psychiatric Sciences, “Aldo Moro” University of Bari, I-70124 Bari, Italy; gdefazio{at}neurol.uniba.i

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Advances in our understanding of the genetics, epidemiology, clinical phenotype and pathological progression of Parkinson's disease (PD) have ushered in an era in which researchers are increasingly looking for therapies that modify (prevent or delay) PD course. Drugs like levodopa, selegiline and rasagiline, which are known to ameliorate the core motor symptoms of PD, have been tested for a possible disease-modifying effect,1–3 and new putative neuroprotective therapies could soon be available.

In order to accurately test neuroprotective effects, drugs need to be challenged with markers of disease progression. To date, data from putative biomarkers assessed in body fluids are limited and inconclusive, structural imaging does not add …

View Full Text


  • Linked articles 240366.

  • Competing interests None.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles